Company Overview of Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company’s product candidates in preclinical stage include INT-767, a...
450 West 15th Street
New York, NY 10011
Founded in 2002
Key Executives for Intercept Pharmaceuticals, Inc.
Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $934.0K
Chief Financial Officer, Treasurer and Secretary
Total Annual Compensation: $556.9K
Chief Medical Officer and Executive Vice President of Development
Total Annual Compensation: $626.5K
Compensation as of Fiscal Year 2013.
Intercept Pharmaceuticals, Inc. Key Developments
FDA Grants Priority Review for Intercept Pharmaceuticals, Inc.'s Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Aug 31 15
Intercept Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application and granted Priority Review for obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC). OCA is being developed to treat PBC patients with an inadequate therapeutic response to, or who are unable to tolerate, ursodeoxycholic acid (UDCA), the only drug currently approved to treat PBC. The FDA has set a target date of February 29, 2016 to take action under the Prescription Drug User Fee Act. The FDA grants Priority Review to medicines that, if approved, would be a significant improvement in the safety or effectiveness of treatment, prevention or diagnosis of serious diseases. A priority review designation means FDA's goal is to take action on the marketing application within six months of acceptance as compared to 10 months under standard review. OCA was previously granted Fast Track designation by FDA. A drug development program with Fast Track designation is afforded greater access to FDA for the purpose of expediting the drug's development, review and potential approval.
Intercept Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 8 15
Intercept Pharmaceuticals, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported licensing revenue of $445,000 compared to $445,000 a year ago. Net loss was $47,894,000 or $1.99 per diluted share compared to net income of $33,470,000 or $1.51 per diluted share a year ago.
For the six months, the company reported licensing revenue of $1,891,000 compared to $851,000 a year ago. Net loss was $87,280,000 or $3.78 per basic and diluted share compared to $212,559,000 or $10.50 per basic and diluted share a year ago.
Intercept Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 05, 2015
Jul 29 15
Intercept Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 05, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|